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A B S T R A C T   
In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and 
non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the 
adequate management of these patients. To date various drugs have been implemented in clinical practice. 
Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the 
current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods 
and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian 
laboratories with high expertise in molecular predictive pathology testing is provided.   
1. BRAF: an overview 
Rapidly accelerated fibrosarcoma (Raf) proteins (including V-Raf 
Murine Sarcoma Viral Oncogene Homolog B [BRAF]) are involved in the 
Raf/extracellular signal-regulated kinase kinase (MEK)/extracellular 
signal-regulated kinase (ERK) pathway (Moodie et al., 1993; Van Aelst 
et al., 1993; Vojtek et al., 1993; Warne et al., 1993; Zhang et al., 1993; 
Matallanas et al., 2011). As early as 1983, the first Raf gene, encoding 
for a serine/threonine kinase protein, was described as a retroviral 
oncogene (Fig. 1) (Rapp et al., 1983; Moelling et al., 1984). Subse-
quently, the cellular homolog proto-oncogene (c-raf) was cloned. 
(Bonner et al., 1985). As far as Raf protein structure is concerned, three 
conserved regions (CRs) with distinct functions can be identified. The 
first is the CR1 site harboring the Ras-binding domain (RBD), which 
enables interaction with Ras proteins, and a cysteine-rich domain (CRD), 
which additionally allows interaction with Ras proteins and is necessary 
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for Raf autoinhibition. (Tran et al., 2005). The second is the CR2 site 
displaying an inhibitory phosphorylation site able to negatively regulate 
interaction with Ras proteins and Raf activation (Dhillon et al., 2002). 
The third is the CR3 site presenting the serine/threonine kinase domain 
(Chong et al., 2001). The BRAF gene was mapped on chromosome 7 
(7q34) and encodes for the BRAF protein, which is involved in the 
mitogen-activated protein (MAP) kinase cascade. Raf proteins play a 
role in the MAP kinase kinase kinase (MAPKKK) cascade (Peyssonnaux 
and Eychène, 2001). This is a highly conserved membrane-to-nucleus 
signaling pathway involved in multiple cell functions including cell 
growth, differentiation, proliferation, senescence and apoptosis (Peys-
sonnaux and Eychène, 2001; Wasylyk et al., 1989; Jamal and Ziff, 1990; 
Kolch et al., 1991). As far as BRAF protein activation is concerned, the 
phosphorylation of S446 is crucial to neutralizing the inhibitory role of 
the N-terminal domain and to obtaining, in association with D449, the 
correct three-dimensional conformation (Tran et al., 2005). 
Since they were first reported in 2002 (Davies et al., 2002), BRAF 
mutations have been identified in several malignancies (Trovisco et al., 
2006; De Roock et al., 2011; Nguyen-Ngoc et al., 2015; Malapelle et al., 
2016; Cheng et al., 2018; Pisapia et al., 2019; Bellevicine et al., 2020). 
More specifically, BRAF mutations are reported in a significant pro-
portion of melanomas (40–60 %), papillary thyroid carcinomas (30–70 
%) and colorectal cancers (5–20 %), whereas a low frequency has been 
reported in lung cancers (1.5–3.5 %) (Davies et al., 2002). 
A classification system was adopted to better define the role of the 
different BRAF mutations (Dankner et al., 2018; Bracht et al., 2019; 
Yaeger and Corcoran, 2019; Frisone et al., 2020). Briefly, class I muta-
tions (including exon 15 p.V600 mutations) enable a constitutive acti-
vation of the MAPK pathway without the need for dimerization and 
upstream RAS activation (Dankner et al., 2018; Bracht et al., 2019; 
Yaeger and Corcoran, 2019; Frisone et al., 2020). Similarly, class II 
mutations (p.G464E/V/R, p.G469A/V/S, p.L597Q/R/S/V and many 
others) are independent of upstream RAS activation, whereas dimer-
ization is necessary in order to activate the signal transduction pathway 
(Dankner et al., 2018; Bracht et al., 2019; Yaeger and Corcoran, 2019; 
Frisone et al., 2020). Finally, class III mutations require upstream acti-
vation and involve a dimerization with wild-type CRAF (Dankner et al., 
2018; Bracht et al., 2019; Yaeger and Corcoran, 2019; Frisone et al., 
2020). 
Here, we focus our attention on BRAF mutations in lung cancer and 
melanoma. 
2. BRAF p.V600 mutation as a positive predictive biomarker in 
melanoma and lung cancer 
The mutational landscape of melanoma is heterogeneous. A recent 
study, based on the use of whole genome sequencing, reported that 
melanoma represents a tumor type harboring a higher mutational rate 
than other neoplasms (Lawrence et al., 2013). In addition, different 
mutational aspects have been identified among the different melanoma 
subtypes (Hayward et al., 2017). Overall, BRAF mutations occur in 
about 40–60 % of melanoma patients (Colombino et al., 2012). More 
specifically, almost all BRAF mutations (97 %) lie in codon 600 of exon 
15 (Ihle et al., 2014). As regards exon 15 codon 600 mutations, up to 90 
% displayed a transversion of T to A involving nucleotide 1799 (c.1799 T 
> A), resulting in the replacement of valine by glutamic acid (p.V600E) 
(Bradish and Cheng, 2014). Other less common substitutions within 
codon 600 involved lysine (p.V600 K, 8–20 %), arginine (p.V600R, 1%), 
methionine (p.V600 M, 0.3 %), and aspartic acid (p.V600D, 0.1 %) 
(Bradish and Cheng, 2014). BRAF-mutated melanomas seem to occur 
more frequently in young people and show more aggressive behavior 
than wild-type cases (Long et al., 2011; Hugdahl et al., 2016). Despite 
this, patients harboring a BRAF exon 15 p.V600 mutation may benefit 
from targeted treatment with tyrosine kinase inhibitors (TKIs), such as 
vemurafenib and dabrafenib, with a significant improvement in 
progression-free survival (PFS) and overall survival (OS) compared to 
standard chemotherapy (Chapman et al., 2011; Hauschild et al., 2012; 
McArthur et al., 2014; Trinh et al., 2014). Another therapeutic strategy 
for BRAF exon 15 p.V600-mutated patients is a BRAF inhibitor plus MEK 
inhibitor (trametinib and cobimetinib) combination, with a dramatic 
improvement in PFS and OS (Ascierto et al., 2016; Long et al., 2016; 
Long et al., 2017; Long et al., 2018). For all these reasons, BRAF exon 15 
p.V600 testing is mandatory in advanced melanoma patients (Coit et al., 
2019). 
BRAF mutations occur very rarely in NSCLC patients (about 1.5–3.5 
%) (Frisone et al., 2020; Leonetti et al., 2018). These mutations are re-
ported more frequently in the adenocarcinoma subtype; more specif-
ically, a micropapillary growth pattern and high expression of thyroid 
transcription factor 1 (TTF-1) were reported for BRAF exon 15 p. 
V600E-mutated cases (Marchetti et al., 2011). As far as epidemiolog-
ical distribution is concerned, although in some experiences BRAF exon 
p.V600E mutations seem to be more frequent in females and 
never-smoker patients, discordant results have been obtained for p. 
V600E and non-p.V600E (Pisapia et al., 2019; Frisone et al., 2020; 
Marchetti et al., 2011; Cardarella et al., 2013; Kinno et al., 2014; Sali-
mian et al., 2018). Discordant results have also emerged regarding the 
prognostic role of the different BRAF mutations in NSCLC patients 
(Marchetti et al., 2011; Paik et al., 2011; Litvak et al., 2014; Tan et al., 
2019). Overall, BRAF exon 15 p.V600E seems to be the most 
commonly-reported mutation (more than 50 %) (Marchetti et al., 2011; 
Cardarella et al., 2013; Paik et al., 2011; Ding et al., 2017; O’Leary et al., 
2019). Noteworthy, in other experiences lung cancers seem to harbor 
more frequently BRAF non-p.V600E respect to p.V600E mutations 
(Pisapia et al., 2019; Noeparast et al., 2016). Moreover, BRAF non-p. 
V600E mutations may coexist with other mutations, in particular Kirs-
ten Rat Sarcoma Viral Oncogene Homolog (KRAS) (Pisapia et al., 2019; 
Salimian et al., 2018; Li et al., 2014; Smit, 2014). As far as therapeutic 
options are concerned, advanced NSCLC patients harboring BRAF p. 
V600E mutations may be treated with the dabrafenib plus trametinib 
combination (Planchard et al., 2016; Planchard et al., 2017). Anecdotal 
reports have shown the possibility of adopting targeted treatments for 
BRAF non-p.V600E-mutated advanced-NSCLC patients (Gautschi et al., 
2015; Kotani et al., 2018; Alvarez and Otterson, 2019; Reyes et al., 
2019). On the whole, the National Comprehensive Cancer Network 
(NCCN) (Ettinger et al., 2018), the College of American Pathologists 
(CAP), the International Association for the Study of Lung Cancer 
Fig. 1. The 3D structure of BRAF protein inibithed by dabrafenib. This figure 
was created by using Mol* PDB ID [Mol* (D. Sehnal, A.S. Rose, J. Kovca, S.K. 
Burley, S. Velankar (2018) Mol*: Towards a common library and tools for web 
molecular graphics MolVA/EuroVis Proceedings. doi:10.2312/ 
molva.20181103), and RCSB PDB]. 
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(IASLC), and the Association for Molecular Pathology (AMP) (Lindeman 
et al., 2018), and American Society of Clinical Oncology (ASCO) 
(Kalemkerian et al., 2018) recommend BRAF mutational assessment for 
advanced NSCLC patients. 
3. Sample management for BRAF mutational assessment in 
melanoma patients 
As far as molecular tests are concerned, melanoma patients have the 
important advantage of high-quantity tissue material (Fig. 2). As a 
matter of fact, in these patients, a wide local excision of the primary 
lesion or metastatic sites (in particular, lymph nodes) is often available 
as starting material from which to extract nucleic acids for molecular 
tests (Hyams et al., 2019). In addition, superficial metastatic sites can be 
approached with fine needle aspiration (FNA) (Doubrovsky et al., 2008). 
The presence of melanin represents a major limitation in melanoma 
specimens. More specifically, melanin may determine unique challenges 
due to the inhibition of the polymerase chain reaction (PCR) (Petty et al., 
2020). Melanin is able to form a reversible complex with the DNA 
polymerase (Eckhart et al., 2000). More specifically, it seems to partic-
ularly affect large amplicons (Eckhart et al., 2000). To overcome this 
limitation, samples with a high melanin content may benefit from 
additional treatments to allow an adequate PCR analysis. Frouin et al. 
proposed three different pre-PCR approaches including the addition of 
bovine serum albumin (BSA), DNA dilution, and DNA purification using 
the NucleoSpin® gDNA Clean-up XS Kit (Frouin et al., 2016). Vicente 
et al. compared six different methods for removing melanin from 
genomic DNA (Agarose Gel Electrophoresis, 1 mg Chelex®-100, Che-
lex®-100 5%, centrifugation, OneStep™ PCR Inhibitor Removal Kit and 
centrifugation plus OneStep™ PCR Inhibitor Removal Kit) showing that 
centrifugation combined with the OneStep™ PCR Inhibitor Removal Kit 
was superior for obtaining adequate BRAF sequencing (ALSA et al., 
2019). When tissue samples are not available, liquid biopsy may be a 
valuable tool for monitoring therapeutic response (Buder-Bakhaya et al., 
2017; Gaiser et al., 2018; Lim et al., 2018). Interestingly, it has been 
demonstrated that an increase in plasma circulating tumor DNA (ctDNA) 
concentration in patients with advanced melanoma harboring a BRAF 
mutation receiving targeted therapies may predict the presence of 
Fig. 2. NSCLC sample collection (A) and preclinical managment for histological samples, starting with formalin fixation and paraffin embedding (B), tissue section 
production (C) and staining (D). After morphological evaluation and diagnosis (E) serial tissue sections were prepared to evaluate clinical relevant predictive 
biomarkers (EGFR, BRAF, ALK, ROS1 and PD –L1). In the lower part of the figure, a fine needle aspiration (F) was reported and a Rapid On Site (ROSE) evaluation 
was schematized, from diff - quick staining (G), to slide preparation (H) for morphological evaluation (I) and, in addition, a cell – block (L) was prepared to obtain 
serial slides (M), that after microscopic evaluation by using an hematoxilin and hesoin staining (N), were used to clinical relevant biomarkers assessment. Credit by 
Biorender.com. 
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relapse earlier than imaging and/or clinical assessments (Gray et al., 
2015). 
4. Sample management for BRAF mutational assessment in non- 
small cell lung cancer patients 
In the current era of personalized medicine, there has been a rapid 
increase in the number of biomarkers to be tested in advanced NSCLC 
patients. According to International guideline recommendations, at least 
Epidermal Growth Factor Receptor (EGFR) and BRAF mutations, 
Anaplastic Lymphoma Kinase (ALK) and ROS Proto-Oncogene 1 (ROS1) 
rearrangements, and the evaluation of the level of Programmed Death- 
Ligand 1 (PD-L1) expression must be tested for treatment decision- 
making (Ettinger et al., 2018; Lindeman et al., 2018; Kalemkerian 
et al., 2018). In addition, a plethora of novel biomarkers have emerged 
(Malapelle et al., 2020; Russo et al., 2020). However, due to significant 
delays in diagnosis, only small tissue samples (histological biopsies or 
cytological specimens) are available for morpho-molecular purposes 
(Ofiara et al., 2012; Wang et al., 2015). As a matter of fact, despite 
having a higher quality of nucleic acids than histological specimens, 
cytological samples are often characterized by a small quantity of 
available tissue (Clark, 2009; Aisner et al., 2016). However, it has been 
extensively demonstrated that cytological specimens represent a valu-
able starting material for molecular analysis (Malapelle et al., 2013; 
Barbareschi et al., 2018; Jain and Roy-Chowdhuri, 2018; Vigliar et al., 
2019) (Fig. 3). In this setting, next-generation sequencing (NGS) tech-
nologies may represent a valid and fascinating way to overcome the 
limits associated with the small quantity of available tissue (Vigliar 
et al., 2015). Unfortunately, a non-negligible percentage (up to 30 %) of 
advanced-stage NSCLC patients do not have an available tissue specimen 
(Herbreteau et al., 2019). In this setting, liquid biopsy may represent a 
valid alternative to tissue specimens for the assessment of the molecular 
status of the different biomarkers (Rijavec et al., 2019; Siravegna et al., 
2019). As for EGFR, the utility of ctDNA has also been demonstrated for 
BRAF mutational assessment (Bracht et al., 2019; Wu et al., 2019; 
Ortiz-Cuaran et al., 2020). 
5. Companion diagnostic and laboratory-developed tests for the 
assessment of BRAF mutations 
5.1. Immunohistochemistry 
Immunohistochemistry (IHC) may be a reliable option for evaluating 
BRAF exon 15 p.V600E mutation (Schirosi et al., 2016). More specif-
ically, in melanoma patients the most commonly-used antibody is the 
monoclonal antibody VE1, which shows cytoplasmic staining (Eriksson 
et al., 2015). The main advantages of IHC are associated with its 
simplicity, low costs, rapid turnaround time (TAT), relatively high 
sensitivity and specificity, and the possibility to evaluate mutant protein 
distribution at single-cell level (Colomba et al., 2013). Its main disad-
vantages are associated with the possibility of false-negative results due 
to heterogeneity or the low concentration of BRAF exon 15 p.V600E and 
the inability to identify BRAF exon 15 p.V600 K or other variants 
(Colomba et al., 2013). By comparing the results obtained by VE1 clone 
and by a PCR-based approach, an overall concordance of 88 % was 
achieved (Hugdahl et al., 2016). A high sensitivity and specificity (97 % 
and 98 %, respectively) were reported by Long et al. by comparing VE1 
clone IHC with a DNA-based approach suggesting the possibility of 
adopting IHC to screen advanced melanoma patients (Long et al., 2013). 
Similar sensitivity and specificity were observed for IHC when results 
were compared to pyrosequencing (85 % and 100 %, respectively) and 
PCR-based approaches (98.6 % and 97.7 %) (Pearlstein et al., 2014; 
Manfredi et al., 2016). 
As far as NSCLC is concerned, due to the possibility of targeting BRAF 
exon 15 p.V600E point mutation alone, IHC may represent a reliable 
approach. Overall, similar results to those obtained in melanoma pa-
tients were obtained for BRAF VE1 clone IHC, as a lung cancer screening 
tool. Ilie et al. demonstrated that IHC using the VE1 clone is a valid 
alternative to molecular biology approaches for detecting BRAF exon 15 
p.V600E point mutation in advanced NSCLC patients, with a sensitivity 
of 90 % and a specificity of 100 % (Ilie et al., 2013). Similarly high 
sensitivity and specificity (96.6 % and 98.6 %, respectively) were ob-
tained by Gow et al. using VE1 clone (Gow et al., 2019). In two different 
cohorts (retrospective and prospective) of advanced NSCLC patients, 
Hofman et al. evaluated the high performance of IHC testing in detecting 
Fig. 3. Melanoma sample collection (A) and preclinical man-
agement for histological samples, starting with formalin fixa-
tion and paraffin embedding (B - C), tissue sections production 
and staining for morphological evaluation and diagnosis (D). 
To evaluate BRAF clinical relevant mutations, DNA was 
extracted (F) and analyzed by using RT – PCR (G) based 
approach or sequencing based assay (H). For RT – PCR based 
approach (G) an amplification curve swift (red to green) was 
schematically represented to underline the impact of melanin 
on DNA amplification. Credit by Biorender.com.   
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BRAF exon 15 p.V600E point mutation. Overall, in a retrospective series 
previously evaluated by NGS and/or pyrosequencing, IHC was able to 
correctly identify all BRAF exon 15 p.V600E mutated patients. Inter-
estingly, no false positives were observed among wild-type and BRAF 
non-p.V600E patients (Hofman et al., 2020). An important advantage in 
terms of TAT has been reported for IHC (three days) compared to 
pyrosequencing (five days) and NGS (14 days) (Hofman et al., 2020). In 
the prospective cohort, BRAF IHC testing showed a positive result in 24 
(3%) out of 699 tumors. Interestingly, in 20 out of 24 cases (83 %) a 
fully-automated real-time PCR (RT-PCR) approach (Idylla, Biocartis, 
Mechelen, Belgium) confirmed the BRAF mutational status. The Authors 
explain that the four negative cases may be false-negative results of 
RT-PCR due to a low tumor cell content (1–5%) with less than a total of 
50 tumor cells observed in the tissue sections (Hofman et al., 2020). 
5.2. Sanger sequencing 
As a general rule, Sanger sequencing represents the gold standard 
technology among the various molecular biology techniques for point 
mutations and small variant detection, on account of its reliability, 
availability, reagent affordability, and relative low costs. However, its 
principal disadvantage is its low sensitivity (Bakker, 2006). As far as 
melanoma patients are concerned, Jurkowska et al. compared the results 
obtained by Sanger sequencing with those obtained by the cobas 4800 
BRAF V600 mutation test (Roche, Basel, Switzerland) (Jurkowska et al., 
2015). Overall, of 236 melanoma samples, a similar percentage of 
mutated cases was achieved for Sanger sequencing and the cobas 4800 
BRAF V600 mutation test (60.9 % and 61.0 %, respectively); the overall 
agreement reported was 95.2 % (Jurkowska et al., 2015). Direct 
sequencing was adopted by Lopez-Rios et al. on 116 melanoma samples 
and the results were compared with those obtained with the cobas 4800 
BRAF V600 mutation test. Overall, a positive percent agreement of 97.7 
% and a negative percent agreement of 95.3 % were achieved with 
Sanger sequencing (Lopez-Rios et al., 2013). In another experience, Qu 
et al. showed that Sanger sequencing is better able to identify BRAF exon 
p.V600-mutated melanomas than the cobas 4800 BRAF V600 mutation 
test (43 % and 35 %, respectively), concluding that Sanger sequencing 
should be adopted in cases of a negative cobas 4800 BRAF V600 mu-
tation test result, to increase the number of patients who may benefit 
from targeted therapy (Qu et al., 2013). 
Sanger sequencing may be a useful approach for detecting EGFR 
sensitizing mutations in advanced NSCLC patients, as shown by Zheng 
et al. (2020). As far as the EGFR mutation rate is concerned, a 21.4 % 
(22/103) mutation rate was reported for 103 analyzed samples; more 
specifically, 20 out of 103 patients (19.5 %) had a sensitizing mutation 
Zheng et al. (2020) A similar detection rate was reported by Sousa et al. 
(2020). Even in this large experience, Sanger sequencing was able to 
establish that 20.5 % (252/1225) of cases harbored at least one mutation 
in the EGFR gene (exons 18–21) Sousa et al. (2020). 
Ellison et al observed that despite having poorer sensitivity than 
Amplification Refractory Mutation System PCR (ARMS-PCR), direct 
sequencing was able to identify mutations in regions not covered by the 
targeted approach (Ellison et al., 2010). Ji et al. compared the results 
obtained with next-generation sequencing (NGS) and Sanger sequencing 
for EGFR mutation and ALK fusion detection (Ji et al., 2019). Overall, 
NGS was able to detect a higher number of EGFR-mutated cases than 
Sanger sequencing (89 vs. 84, respectively), due to a very low abun-
dance of mutated allele (<5%) Ji et al., 2019) Conversely, Sanger 
sequencing was able to detect an ALK-rearranged case, which was 
further confirmed with ARMS PCR, that had been overlooked by NGS (Ji 
et al., 2019). 
5.3. Pyrosequencing and matrix assisted laser desorption ionization - time 
of flight (MALDI – TOF) 
Unlike Sanger sequencing, pyrosequencing does not use labeled 
dideoxynucleotides; rather its “sequencing by synthesis” involves an 
enzymatic reaction that ultimately produces light (Ronaghi et al., 1998). 
Colomba et al. compared four different methods (IHC, pyrosequencing, 
RT-PCR, Sanger sequencing) to detect BRAF exon 15 p.V600 mutations 
in advanced melanoma patients (Colomba et al., 2013). Interestingly, in 
the 89 patients showing an adequate result for all methods, pyrose-
quencing was the only technique able to correctly identify all BRAF exon 
15 p.V600 and BRAF exon 15 p.V600E point mutations without 
false-positive results (100 % sensitivity and specificity) (Colomba et al., 
2013). The Authors concluded that pyrosequencing may be useful in the 
case of negative or uninterpretable IHC results for the detection of BRAF 
exon 15 p.V600E (Colomba et al., 2013). Pyrosequencing has demon-
strated its utility in detecting BRAF non-p.V600E mutations, as reported 
by (Heinzerling et al. (2013). In this study, a higher percentage of pa-
tients harboring these rare BRAF mutations were detected by pyrose-
quencing (92.9 %, 13/14) than by the cobas 4800 BRAF V600 mutation 
test (50.0 %, 7/14) and IHC (21.4 %, 3/14) Heinzerling et al. (2013). 
This highly sensitive, reliable, and time-saving approach may avoid the 
overlooking of rare mutations that could result in a subset of patients 
being excluded from targeted therapies. Ihle et al. analyzed a 
pre-selected cohort of 82 cancer samples (also including melanoma and 
lung cancer patients). Overall, pyrosequencing was able to detect 100 % 
of the mutations down to 5% allele frequency but only showed 90 % 
specificity (Ihle et al., 2014). 
The potential of Matrix-assisted laser desorption/ionization time of 
flight (MALDI-TOF) for DNA analysis was reported in 1995 (Tang et al., 
1995). In order to use this analysis technique, nucleic acid molecules are 
extracted and deposited on a dedicated matrix before being irradiated by 
laser to induce their desorption and ionization; the ionized DNA mole-
cules pass through a flight tube connected directly to a detector (Tang 
et al., 1995). Separation occurs by the time of flight, which is propor-
tional to the mass of the individual DNA molecule (Tang et al., 1995). In 
recent years, MALDI-TOF has shown feasibility for single nucleotide 
genotyping in particular (Sauer et al., 2003). Different approaches have 
been implemented to improve the practicability of this technology, 
based on either a locus-specific PCR step followed by a primer extension, 
invader reaction, or hybridization steps with or without exonuclease 
digestion. In addition, to improve the multiplex power of MALDI – TOF, 
Sequenom optimized the primer extension reactions by using acyclic 
mass-modified base terminators that achieve at least 16-Dalton gaps 
between the four possible bases incorporated into a single base exten-
sion. This innovative approach led to the implementation of MALDI – 
TOF in routine predictive molecular pathology as high-throughput 
SNP-based genotype methods, representing a bridge between conven-
tional methods, such as Sanger sequencing and RT–PCR, and NGS. 
5.4. Real-time PCR 
RT-PCR is a targeted method able to detect known mutations (Nollau 
and Wagener, 1997). As a general rule, the RT-PCR approach adopts a 
set of primers that specifically target BRAF mutations and another able 
to identify the wild-type sequence (Cheng et al., 2018). To date, the 
cobas 4800 BRAF V600 mutation test or THxID-BRAF kit have obtained 
Food and Drug Administration (FDA) approval in melanoma patients for 
the detection of BRAF exon 15 p.V600 mutations in order to administer 
TKI treatments in advanced-stage melanoma patients (Marchant et al., 
2014). In the experience by Anderson et al., the cobas 4800 BRAF V600 
mutation test was compared with Sanger sequencing in 477 melanoma 
samples (Anderson et al., 2012). Overall, all cases were successfully 
tested with the cobas 4800 BRAF V600 mutation test, whereas a failure 
rate of 9.2 % was reported for Sanger sequencing (Anderson et al., 
2012). Mourah et al. compared the results obtained using the cobas 
4800 BRAF V600 mutation test with various other techniques (including 
Sanger sequencing, pyrosequencing, allele-specific PCR, SNaPshot and 
high-resolution melting (HRM) analysis) (Mourah et al., 2015). Overall, 
the frequency of BRAF exon 15 p.V600 mutations detected was slightly 
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higher for the other techniques than for the cobas 4800 BRAF V600 
mutation test (35.7 % vs. 34.0 %, respectively), whereas wild-type cases 
were detected with a higher frequency by the cobas 4800 BRAF V600 
mutation test (63.3 % vs. 62.9 %) (Mourah et al., 2015). These data 
confirm the high clinical efficacy of the cobas 4800 BRAF V600 mutation 
test. Marchant et al. used the THxID BRAF diagnostic test on 113 mel-
anoma samples (Marchant et al., 2014). Overall, just one inadequate 
case (0.9 %) was reported. Interestingly, complete concordance (100 %) 
between Sanger sequencing and the THxID BRAF test was observed, 
whereas between the THxID BRAF test and HRM the concordance rate 
was 97.3 % (Marchant et al., 2014). 
As for melanoma, RT-PCR using Therascreen (Qiagen, Hilden, Ger-
many) is an FDA-approved real-time PCR approach for detecting 21 or 
29 EGFR mutations in exons 18, 19, 20, and 21 (Allegrini et al., 2012). In 
the IPASS clinical trial, the DxS EGFR mutation test kit was used to 
evaluate 29 EGFR mutations (19 deletions in exon 19, exon 21 p.L858R, 
exon 20 p.T790 M, exon 21 p.L861Q, exon 18 p.G719S/A/C, exon 20 p. 
S768I, and three insertions in exon 20), in order to administer the 
first-generation TKI gefitinib (Mok et al., 2009). Overall, 59.7 % of 
tested patients showed an EGFR mutation (Mok et al., 2009). In the 
IFUM phase IV clinical trial on gefitinib, an EGFR mutational rate of 13.7 
% was reported using the Therascreen EGFR 29 kit (Douillard et al., 
2014). In 2009, The cobas EGFR mutation test obtained FDA approval as 
a companion diagnostic for erlotinib in advanced NSCLC patients 
(Malapelle et al., 2017). In a retrospective analysis of the EURTAC 
clinical trial, an overall concordance of 96 % and a faster turnaround 
time (TAT) were reported for the cobas EGFR mutation test than a 
laboratory-developed RT-PCR test (Benlloch et al., 2014). The cobas 
EGFR mutation test v2 is a RT-PCR method able to detect 42 different 
EGFR gene mutations in exons 18, 19, 20, and 21 and has been approved 
by the FDA for the liquid biopsy setting (Malapelle et al., 2017). RT-PCR 
is also suitable for EGFR analysis on cytological samples, as reported by 
Malapelle et al. (TaqMan assay) and De Luca et al (Idylla, Biocartis, 
Mechelen, Belgium) (Malapelle et al., 2013; De Luca et al., 2017; De 
Luca et al., 2019). 
5.5. Next-generation sequencing 
NGS is a fascinating technology able to analyze several mutations for 
different patients, simultaneously (Rothberg et al., 2011). Briefly, 
although different platforms are currently commercially available, the 
NGS workflow is characterized by four sequential phases: library gen-
eration, clonal amplification, massive parallel sequencing, and data 
analysis (Vigliar et al., 2015). 
Due to its higher costs and longer TAT, Zhu et al. suggested adopting 
NGS for advanced melanomas showing a negative result with allele- 
specific BRAF exon 15 p.V600E/K PCR (Zhu et al., 2018). The Authors 
highlighted the higher sensitivity of the NGS approach compared to the 
allele-specific PCR approach, enabling the identification of 16 action-
able mutations in 24 negative advanced melanoma patients (Zhu et al., 
2018). However, the costs and TAT of NGS may be more favorable when 
other genes are analyzed. In the study by de Unamuno Bustos et al., 
about 85 % of analyzed melanomas harbored at least one mutation (de 
Unamuno Bustos et al., 2017). More specifically, as expected, 50 % of 
samples showed a BRAF mutation (the vast majority were exon 15 p. 
V600E (80 %; 40/50) (de Unamuno Bustos et al., 2017). A similar result 
in terms of BRAF mutation rate was reported by Lokhandwala et al. 
(2019). Overall, using an NGS approach 42 % of cases were reported as 
being BRAF-mutated cases (of which 76 % in the exon 15 codon 600) 
Lokhandwala et al. (2019). NGS may also be useful for detecting rare 
actionable mutations that are overlooked by targeted methods. As re-
ported by Proietti et al., NGS was able to detect a rare variant of BRAF 
exon 15 p.V600E (c.1799_1800TG > AA) that was overlooked by an 
RT-PCR approach (Proietti et al., 2020). 
As far as NSCLC patients are concerned, using the AmpliSeq Cancer 
Hotspot Panel v2 (ThermoFisher Scientifics, Waltham, MA), Salimian 
et al. were able to identify 36 BRAF- mutated lung adenocarcinomas 
(Salimian et al., 2018). Interestingly, ten harbored a BRAF exon 15 p. 
V600E (Salimian et al., 2018). Similar results were obtained using a 
narrow custom NGS panel (SiRe®). Pepe et al. and Pisapia et al. were 
able to detect 14 (4.8 %) BRAF-mutated cases among 294 analyzed 
advanced NSCLC patients on tissue specimens (histological and cyto-
logical) (Pisapia et al., 2019; Pepe et al., 2019). In particular, eight cases 
showed a targetable BRAF exon 15 p.V600E, without any other driver 
mutations (Pisapia et al., 2019; Pepe et al., 2019). In the study by 
Fumagalli et al., a large number of advanced NSCLC patients (n = 535) 
were evaluated using a 22-gene panel on the Ion Torrent Personal 
Genome Machine (PGM, ThermoFisher Scientifics) platform (Fumagalli 
et al., 2018). Overall, 23 (4.3 %) of the 535 tumors harbored a BRAF 
mutation. Interestingly, 14 cases harbored a BRAF exon 15 alteration, 
but a p.V600E point mutation was only observed in six cases (Fumagalli 
et al., 2018). In a large-scale experience, Lin et al. adopted 
Capture-based NGS sequencing on either plasma or tissue samples ob-
tained from 8405 Chinese stage I–IV NSCLC patients (Lin et al., 2019). 
Overall, BRAF mutations were reported in 238 (2.8 %) patients (Lin 
et al., 2019). Of these, the most common mutations were identified in 
codon 600 (32 %) (Lin et al., 2019). As far as the liquid biopsy setting is 
concerned, Bracht et al. used a targeted ctDNA NGS assay (Guar-
dant360®, Guardant Health Inc., Redwood City, CA), and results were 
correlated with patient outcome. Overall, the Authors were able to 
identify 17 (9.2 %) BRAF-mutated cases amongst the 185 patients 
analyzed, of which four (23.5 %) were BRAF exon 15 p.V600E (Bracht 
et al., 2019). 
6. Integrated clinical report for BRAF mutational evaluation: 
from morphology to molecular biology 
Molecular reports play a key role in the molecular predictive pa-
thology workflow and should exhaustively report all relevant informa-
tion to ensure the best treatment option for cancer patients (Cree et al., 
2014; Li et al., 2017). To this end, in order to avoid any misinterpreta-
tion, effective communication between the different professionals 
involved in this field is essential. As a matter of fact, reports that are 
incomplete or difficult to understand may contribute to errors in cancer 
patient management. Molecular reports should therefore be short, easy 
to interpret and contain the salient information that could be of interest 
for the administration of the best treatment option. Firstly, molecular 
reports should contain patients’ unique identifiers (name, surname, date 
of birth, and identification number). Additional relevant information 
regards the ward or service, the date, the type of sample, and the name of 
clinician requesting the molecular analysis (Cree et al., 2014). The body 
of the report should contain the pre-analytical information (e.g. per-
centage of neoplastic cells, fixation problems, presence of contaminants 
that could influence the analysis) and the mutational status of the 
analyzed biomarkers (in both nucleotide and aminoacidic forms) (Cree 
et al., 2014; Li et al., 2017). Other important information includes the 
variant allele frequency and coverage of detected alterations. The report 
should contain a clinical interpretation of the detected variants in order 
to guide clinicians in the choice of the best treatment for their patients, 
information that may be supported by literature citations. Methodo-
logical data, regarding the type of test adopted, the reference range, the 
limit of detection [LOD], and the NGS parameters run should be pro-
vided at the end of the report (Li et al., 2017). 
7. Treatment decision-making 
7.1. Melanoma 
As discussed previously, despite its highly aggressive behavior, pa-
tients with BRAF-mutated melanoma may be treated with targeted 
therapies (Luther et al., 2019). Vemurafenib was the first BRAF inhibitor 
to be approved by the FDA for the treatment of advanced BRAF exon 15 
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p.V600E-mutated melanoma patients. In a large phase III clinical trial, 
vemurafenib (BRAF inhibitor) demonstrated a significant increase in 
PFS and OS in advanced-stage BRAF exon 15 p.V600E-mutated and 
previously untreated melanoma patients compared to dacarbazine 
(Chapman et al., 2011). Subsequently, in an update study of the BRIM-3 
clinical trial, with an extended follow-up for the entire population, in the 
vemurafenib group an increase in survival was observed compared to 
dacarbazine, not only in BRAF exon 15 p.V600E, but also in BRAF exon 
15 p.V600 K previously-untreated melanoma patients (McArthur et al., 
2014). Similar results compared to standard chemotherapy (dacarba-
zine) were reported in BRAF-mutated advanced melanoma patients 
(exon 15 p.V600E and exon 15 p.V600 K) treated with another BRAF 
inhibitor (dabrafenib) as monotherapy (Hauschild et al., 2012; Haus-
child et al., 2020). Interesting results, in terms of OS and PFS in patients 
with BRAF exon 15 p.V600-mutant advanced melanoma, were obtained 
for BRAF inhibitor plus MEK inhibitor combinations. In 
previously-untreated unresectable or metastatic melanoma patients 
harboring a BRAF exon 15 p.V600E/K mutation, Long et al. reported a 
higher PFS (9.3 vs. 8.8 months), OS (93 % vs. 85 %) and overall response 
rate (ORR) (67 % vs. 51 %) when patients were treated with the dab-
rabenib plus trametinib combination than with dabrafenib alone (Long 
et al., 2016; Long et al., 2017; Long et al., 2018; Long et al., 2014). In the 
coBRIM clinical trial, previously-untreated advanced BRAF exon 15 p. 
V600-mutated melanoma patients were randomized to receive vemur-
afenib (BRAF inhibitor) plus cobimetinib (MEK inhibitor) or vemur-
afenib plus placebo. Overall, higher median PFS (9.9 vs. 6.2 months), 
complete or partial responses (68 % vs. 45 %; more specifically, com-
plete responses were 10 % vs. 4%), and OS (9-month survival rate of 81 
% vs. 73 %) were observed in the combination group (vemurafenib plus 
cobimetinib) than in the group administered vemurafenib as a single 
agent (Larkin et al., 2014). In addition, the combination was not asso-
ciated with a significantly increase of adverse events of grade 3 or higher 
respect to vemurafenib alone (65 % vs. 59 %) (Larkin et al., 2014). More 
recently, in pre-clinical models, it has been highlighted a correlation 
between the resistance of melanoma cells to BRAF and MEK inhibitors 
with an increased immunogenicity to natural killer (NK) cells (Frazao 
et al., 2020). However, due to the possibility of tumor escaping from NK 
cells activity, a boosting of NK cells may be required in association with 
targeted therapies to improve antitumor activity (Frazao et al., 2020). 
As far as immunotherapy is concerned, various studies have evalu-
ated the efficacy of a targeted therapy plus immunotherapy combination 
approach. The rationale behind this association was that in preclinical 
murine models, it was observed that BRAF inhibitors may increase 
tumor infiltration by adoptively-transferred T cells (Liu et al., 2013). 
The first study conducted to evaluate the efficacy of a combination 
approach was carried out by Ribas et al. (2013). In this phase I clinical 
trial, vemurafenib plus ipilimumab (an anti-Cytotoxic T-Lymphocyte 
Antigen 4 [CTLA-4] monoclonal antibody) were administered to 
previously-untreated patients with BRAF or MEK inhibitors, and 
anti-CTLA4 (Ribas et al. (2013). Interestingly, the study was closed due 
to severe liver toxicity (Liu et al., 2013). A similar fate befell the dab-
rafenib, trametinib, and ipilimumab triple combination in metastatic 
BRAF exon 15 p.V600E/K-mutated melanoma patients due to grade 3 
colitis complicated by perforation (Minor et al., 2015). Conversely, the 
dabrafenib plus ipilimumab combination was seen to be well tolerated 
(Minor et al., 2015). Different results in terms of tolerability emerged for 
anti-Programmed death 1 (PD-1) and anti-PD-L1 monoclonal antibodies. 
Promising results have been reported for the durvalumab or pem-
brolizumab plus dabrafenib plus trametinib combination (ORR 69 % and 
67 %, respectively) (Pavlick et al., 2019). In a phase Ib clinical trial, 
Sullivan et al. reported promising anti-tumor activity with important but 
manageable toxicity for the atezolizumab plus cobimetinib plus 
vemurafenib triplet in BRAF exon 15 p.V600-mutated advanced mela-
noma patients (objective response rate was 71.8 %) (Sullivan et al., 
2019). More recently, the efficacy of the combination of immunotherapy 
(atezolizumab) and targeted therapy (vemurafenib and cobimetinib) in 
BRAF p.V600-mutated advanced melanoma patients was reported in a 
phase III clinical trial (IMspire150) (Gutzmer et al., 2020). In this study, 
the combination showed a significant increase in PFS respect to the as-
sociation vemurafenib and cobimetinib (15.1 vs. 10.6 months) with 
acceptable safety and tolerability (Gutzmer et al., 2020). Following 
these interesting results, the FDA approved the combination for the 
treatment of advanced melanoma patients harboring BRAF p.V600 
mutations (FDA Approves Genentech’s Tecentriq plus Cotellic and Zel-
boraf for People With Advanced Melanoma [news release], 2020]). 
Either in target treatment or immunotherapy, 18F-fluorodeox-
yglucose positron emission tomography/computed tomography (18F- 
FDG PET/CT) seems to be a more valuable option than CT for predicting 
and monitoring therapy response and toxicity (Olthof et al., 2020; Bis-
schop et al., 2020). 
7.2. Lung Cancer 
A number of different experiences have been reported regarding 
treatment for BRAF-mutated advanced NSCLC patients (Giopanou and 
Pintzas, 2020). Cardarella et al. reported that advanced NSCLC patients 
with BRAF mutations (p.V600E or non-p.V600E) treated with the 
platinum-based combination approach did not show a significant dif-
ference in PFS and OS to BRAF wild-type patients (Cardarella et al., 
2013) Interestingly, BRAF exon 15 p.V600E-mutated patients showed a 
shorter PFS than non-p.V600E-mutated patients (4.1 vs. 8.9 months; p =
0.297) (Cardarella et al., 2013). Similar results were reported by Ding 
et al. (2017). Conversely, Dagogo-Jack et al. reported shorter PFS and 
OS for class II and class III mutations (non-p.V600) when treated with 
chemotherapy (Dagogo-Jack et al., 2019). As far as the targeted treat-
ment approach is concerned, advanced NSCLC patients harboring BRAF 
exon 15 p.V600E- or non-p.V600E-mutations receive a different treat-
ment schedule. With regard to targeted treatment, Gautschi et al. re-
ported the efficacy of targeted therapy (vemurafenib, dabrafenib, 
sorafenib) in advanced BRAF-mutated NSCLC patients (Gautschi et al., 
2015). Interestingly, OS was higher for patients with BRAF exon 15 p. 
V600E mutations than non-p.V600E mutations (25.3 vs. 11.8 months) 
(Gautschi et al., 2015). More recently, Mazieres et al. confirmed the 
greater efficacy of vemurafenib in the BRAF p.V600 group than in non-p. 
V600 patients (Mazieres et al., 2020). As reported for melanoma pa-
tients, BRAF exon 15 p.V600E-mutated patients may benefit from a 
BRAF inhibitor (dabrafenib) plus MEK inhibitor (trametinib) combina-
tion (Planchard et al., 2016; Planchard et al., 2017). Overall, in a phase 
II clinical trial, the combination (dabrafenib plus trametinib) demon-
strated promising results in terms of overall response, prolonged dura-
tion of response, and manageable toxicity in previously-treated 
(Planchard et al., 2016) and untreated (Planchard et al., 2017) advanced 
NSCLC patients harboring the BRAF exon 15 p.V600E mutation. Less 
evidence is available to suggest the role of targeted treatments in non-p. 
V600E-mutated cases. In a cell line setting, Kotani et al. showed that the 
inhibition of the MAPK pathway by MEK inhibitor monotherapy (tra-
metinib) was insufficient in lung cancer cell lines harboring BRAF class II 
and III mutations (Kotani et al., 2018). This was attributed to ERK 
activation through the receptor tyrosine kinase (RTK) pathway (e.g. 
EGFR) with the activation of RAS and CRAF (Kotani et al., 2018). The 
Authors hypothesized the possibility of adopting the MEK inhibitors plus 
TKI combination for BRAF non-p.V600E patients (Kotani et al., 2018). 
Two case reports showed the efficacy of sorafenib (a multi-target kinase 
inhibitor able to block CRAF, BRAF, KIT Proto-Oncogene, Receptor 
Tyrosine Kinase [c-KIT], Fms Related Receptor Tyrosine Kinase 3 
[FLT-3], Rearranged During Transfection [RET], vascular endothelial 
growth factor receptor 2 [VEGFR-2], VEGFR-3 and platelet-derived 
growth factor receptor alpha [PDGFRA]) in BRAF non-p.V600-mutated 
patients (exon 11 p.G469R and exon 11 p.G469 V) (Sereno et al., 
2015; Casadei Gardini et al., 2016). 
Another possible approach in BRAF-mutated patients could be ERK 
inhibitors (e.g. ulixertinib, an ERK1/2 kinase inhibitor) (Sullivan et al., 
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2018) and pan-RAF inhibitors (e.g. LY3009120) (Sullivan et al., 2020). 
As far as immunotherapy is concerned, Dudnik et al. reported 
favorable activity in both BRAF exon 15 p.V600E- and BRAF non-p. 
V600E-mutated advanced NSCLC patients (Dudnik et al., 2018). 
Conversely, Tan et al., in a small study highlighted the greater efficacy of 
chemotherapy over immunotherapy in BRAF-mutated patients (Tan 
et al., 2020). Guisier et al. observed an objective response rate among 
BRAF mutated NSCLC patients treated with immunotherapy of 30 % (33 
% non-p.V600E, 26 % exon 15 p.V600E), similar to the results obtained 
in unselected pretreated NSCLC patients (Guisier et al., 2020). 
8. BRAF mutations in lung cancer and melanoma: Italian real- 
world perspectives 
In order to evaluate the real-world data on BRAF mutation assess-
ment in both melanoma and NSCLC patients, we carried out an online 
survey involving nine laboratories with specialized certified expertise in 
this field, by asking the different centers to retrieve molecular data for 
the 2018–2020 period. All information regarding human material were 
managed using anonymous numerical codes, and all samples were 
handled in compliance with the Declaration of Helsinki (http://www. 
wma.net/en/30publications/10policies/b3/). 
As far as BRAF analysis in NSCLC patients is concerned, a total of 
3102 cases were retrieved from the digital archives. Overall, BRAF 
mutational status was assessed by NGS in the majority (5/9, 55.6 %) of 
the laboratories, ensuring an optimization of the starting material for the 
analysis of all clinically-relevant biomarkers, simultaneously. A MALDI- 
TOF-based approach was adopted by one institution (11.1 %). Both 
commercially-available and custom panels were adopted for the anal-
ysis. After highly-multiplexed approaches, the RT-PCR method was the 
second most frequently-adopted technique (3/9, 33.3 %). This approach 
may be useful for BRAF mutational status evaluation in this patient 
setting, due to need to identify BRAF exon 15 p.V600E alone for targeted 
treatment purposes (Fig. 4). As expected, only a minimal percentage of 
cases (167/3102, 5.4 %) harbored a BRAF mutation. Focusing the 
attention on the targetable BRAF exon 15 p.V600E, only a very small 
number of patients (71/3102, 2.3 %) may be suitable for dabrafenib plus 
trametinib combination therapy (Fig. 4). 
Of the nine laboratories involved in the study, just four (44.4 %) 
performed and shared the results regarding BRAF mutational status in 
their routine practice. In the 2018–2020 period, a total of 801 melanoma 
cases underwent BRAF mutational status assessment. As regards the 
platform adopted, two laboratories (50.0 %) prefer an RT-PCR 
approach, whereas the other two laboratories adopted NGS or MOLDI- 
TOF approaches. Overall, 380 patients (47.4 %) harbored a BRAF mu-
tation. BRAF exon 15 p.V600 actionable mutations were the mutations 
most commonly detected (368/801, 45.9 %), with a higher represen-
tation of BRAF exon 15 p.V600E (312/801, 39.0 %), followed by p.V600 
K (48/801, 6.0 %), p.V600R (6/801, 0.7 %), p.V600D (1/801, 0.1 %) 
and p.V600 M (1/801, 0.1 %) (Fig. 5). 
9. Conclusion 
BRAF mutations play a key role in the management of both advanced 
melanoma and advanced NSCLC patients. Several clinical trials have 
demonstrated the efficacy of different targeted therapies (BRAF in-
hibitors, MEK inhibitors, combination therapies, immunotherapy) in 
BRAF-mutated patients. For these reasons, BRAF mutational assessment 
is critical for adequate management of advanced melanoma and NSCLC 
patients. In our real-word experience, a total of 3102 advanced NSCLC 
and 801 melanoma patients were assessed for BRAF mutational status. 
Amongst the NSCLC patients, as expected, only a minimal percentage of 
cases (5.4 %) harbored a BRAF mutation. Considering BRAF exon 15 p. 
V600E, a total of 71 patients (71/3102, 2.3 %) may be eligible for 
treatment with the dabrafenib plus trametinib combination. Of the total 
of 801 tested melanoma patients, 45.9 % (368/801) of patients harbored 
a BRAF exon p.V600 mutation and were potentially eligible for targeted 
therapy. As reported in literature and in our experience, several methods 
can be adopted to assess BRAF mutational status. IHC may be a reliable 
tool due to its simplicity, low costs, rapid TAT, high sensitivity and 
specificity, and its ability to identify mutant protein distribution at 
single-cell level. However, it is important to bear in mind the fact that 
false-negative results are possible due to heterogeneity or low concen-
trations of BRAF exon 15 p.V600E and the inability to identify other 
clinical relevant variants. Direct sequencing still represents the gold 
standard for the detection of point mutations and small variant detec-
tion, due to the technique’s reliability, availability, reagent afford-
ability, and relatively low costs. However, its poor sensitivity constitutes 
an important limitation. Despite having a higher sensitivity than direct 
Sequencing, the RT-PCR approach showed a limited reference range. 
NGS may be a reliable approach for overcoming these limits. This 
fascinating technology enables the analysis of different hotspot muta-
tions for different patients, simultaneously. However, its higher costs, 
longer TAT and the need for highly-skilled personnel and careful vali-
dation precludes its availability in some predictive molecular pathology 
laboratories. 
To conclude, careful attention should be paid to the detection of 
BRAF mutations due to the considerable efficacy of targeted treatment in 
BRAF-mutated cancer patients. Due to the high specificity of the 
different methods adopted and to avoid the risk and under-treatment of 
false-negative cases, careful attention should also be dedicated to con-
firming those cases with a negative result, especially when NGS methods 
are adopted. 
Fig. 4. Italian real word BRAF mutations distribution in NSCLC patients. Credit by Biorender.com.  
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Jurkowska, M., Gos, A., Ptaszyński, K., Michej, W., Tysarowski, A., Zub, R., Siedlecki, J. 
A., Rutkowski, P., 2015. Comparison between two widely used laboratory methods 
in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous 
melanoma metastases to the lymph nodes. Int. J. Clin. Exp. Pathol. 8, 8487–8493. 
Kalemkerian, G.P., Narula, N., Kennedy, E.B., Biermann, W.A., Donington, J., Leighl, N. 
B., Lew, M., Pantelas, J., Ramalingam, S.S., Reck, M., Saqi, A., Simoff, M., Singh, N., 
Sundaram, B., 2018. Molecular testing guideline for the selection of patients with 
lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society 
of Clinical Oncology Endorsement of the College of American Pathologists/ 
International Association for the Study of Lung Cancer/Association for Molecular 
Pathology Clinical Practice Guideline Update. J. Clin. Oncol. 36, 911–919. 
Kinno, T., Tsuta, K., Shiraishi, K., Mizukami, T., Suzuki, M., Yoshida, A., Suzuki, K., 
Asamura, H., Furuta, K., Kohno, T., Kushima, R., 2014. Clinicopathological features 
of nonsmall cell lung carcinomas with BRAF mutations. Ann. Oncol. 25, 138–142. 
Kolch, W., Heidecker, G., Lloyd, P., Rapp, U.R., 1991. Raf-1 protein kinase is required for 
growth of induced NIH/3T3 cells. Nature 349, 426–428. 
Kotani, H., Adachi, Y., Kitai, H., Tomida, S., Bando, H., Faber, A.C., Yoshino, T., Voon, D. 
C., Yano, S., Ebi, H., 2018. Distinct dependencies on receptor tyrosine kinases in the 
regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung 
cancers. Oncogene 37, 1775–1787. 
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Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Dutriaux, C., 
Garbe, C., Sovak, M.A., Chang, I., Choong, N., Hack, S.P., McArthur, G.A., Ribas, A., 
2014. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. 
J. Med. 371, 1867–1876. 
Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., 
Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., Kiezun, A., Hammerman, P.S., 
McKenna, A., Drier, Y., Zou, L., Ramos, A.H., Pugh, T.J., Stransky, N., Helman, E., 
Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M.L., 
Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., 
Heiman, D.I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. 
M., Lohr, J., Landau, D.A., Wu, C.J., Melendez-Zajgla, J., Hidalgo-Miranda, A., 
Koren, A., McCarroll, S.A., Mora, J., Crompton, B., Onofrio, R., Parkin, M., 
Winckler, W., Ardlie, K., Gabriel, S.B., Roberts, C.W.M., Biegel, J.A., Stegmaier, K., 
Bass, A.J., Garraway, L.A., Meyerson, M., Golub, T.R., Gordenin, D.A., Sunyaev, S., 
Lander, E.S., Getz, G., 2013. Mutational heterogeneity in cancer and the search for 
new cancer-associated genes. Nature 499, 214–218. 
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., 
Planchard, D., 2018. BRAF in non-small cell lung cancer (NSCLC): pickaxing another 
brick in the wall. Cancer Treat. Rev. 66, 82–94. 
Li, S., Li, L., Zhu, Y., Huang, C., Qin, Y., Liu, H., Ren-Heidenreich, L., Shi, B., Ren, H., 
Chu, X., Kang, J., Wang, W., Xu, J., Tang, K., Yang, H., Zheng, Y., He, J., Yu, G., 
Liang, N., 2014. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic 
mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese 
cohorts. Br. J. Cancer 110, 2812–2820. 
U. Malapelle et al.                                                                                                                                                                                                                              
Critical Reviews in Oncology / Hematology 156 (2020) 103118
12
Li, M.M., Datto, M., Duncavage, E.J., Kulkarni, S., Lindeman, N.I., Roy, S., 
Tsimberidou, A.M., Vnencak-Jones, C.L., Wolff, D.J., Younes, A., Nikiforova, M.N., 
2017. Standards and guidelines for the interpretation and reporting of sequence 
variants in cancer: a joint consensus recommendation of the association for 
molecular pathology, american society of clinical oncology, and college of american 
pathologists. J. Mol. Diagn. 19, 4–23. 
Lim, S.Y., Lee, J.H., Diefenbach, R.J., Kefford, R.F., Rizos, H., 2018. Liquid biomarkers in 
melanoma: detection and discovery. Mol. Cancer 17, 8. 
Lin, Q., Zhang, H., Ding, H., Qian, J., Lizaso, A., Lin, J., Han-Zhang, H., Xiang, J., Li, Y., 
Zhu, H., 2019. The association between BRAF mutation class and clinical features in 
BRAF-mutant Chinese non-small cell lung cancer patients. J. Transl. Med. 17, 298. 
Lindeman, N.I., Cagle, P.T., Aisner, D.L., Arcila, M.E., Beasley, M.B., Bernicker, E.H., 
Colasacco, C., Dacic, S., Hirsch, F.R., Kerr, K., Kwiatkowski, D.J., Ladanyi, M., 
Nowak, J.A., Sholl, L., Temple-Smolkin, R., Solomon, B., Souter, L.H., 
Thunnissen, E., Tsao, M.S., Ventura, C.B., Wynes, M.W., Yatabe, Y., 2018. Updated 
molecular testing guideline for the selection of lung cancer patients for treatment 
with targeted tyrosine kinase inhibitors: guideline from the college of american 
pathologists, the international association for the study of lung cancer, and the 
association for molecular pathology. Arch. Pathol. Lab. Med. 142, 321–346. 
Litvak, A.M., Paik, P.K., Woo, K.M., Sima, C.S., Hellmann, M.D., Arcila, M.E., 
Ladanyi, M., Rudin, C.M., Kris, M.G., Riely, G.J., 2014. Clinical characteristics and 
course of 63 patients with BRAF mutant lung cancers. J. Thorac. Oncol. 9, 
1669–1674. 
Liu, C., Peng, W., Xu, C., Lou, Y., Zhang, M., Wargo, J.A., Chen, J.Q., Li, H.S., 
Watowich, S.S., Yang, Y., Tompers Frederick, D., Cooper, Z.A., Mbofung, R.M., 
Whittington, M., Flaherty, K.T., Woodman, S.E., Davies, M.A., Radvanyi, L.G., 
Overwijk, W.W., Lizée, G., Hwu, P., 2013. BRAF inhibition increases tumor 
infiltration by T cells and enhances the antitumor activity of adoptive 
immunotherapy in mice. Clin. Cancer Res. 19, 393–403. 
Lokhandwala, P.M., Tseng, L.H., Rodriguez, E., Zheng, G., Pallavajjalla, A., Gocke, C.D., 
Eshleman, J.R., Lin, M.T., 2019. Clinical mutational profiling and categorization of 
BRAF mutations in melanomas using next generation sequencing. BMC Cancer 19, 
665. 
Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., 
Hughes, T.M., Thompson, J.F., Scolyer, R.A., Kefford, R.F., 2011. Prognostic and 
clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. 
Oncol. 29, 1239–1246. 
Long, G.V., Wilmott, J.S., Capper, D., Preusser, M., Zhang, Y.E., Thompson, J.F., 
Kefford, R.F., von Deimling, A., Scolyer, R.A., 2013. Immunohistochemistry is highly 
sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am. 
J. Surg. Pathol. 37, 61–65. 
Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., 
Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., Chiarion Sileni, V., Lebbe, C., 
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Giuffrè, G., Bellevicine, C., Troncone, G., 2016. Less frequently mutated genes in 
colorectal cancer: evidences from next-generation sequencing of 653 routine cases. 
J. Clin. Pathol. 69, 767–771. 
Malapelle, U., Sirera, R., Jantus-Lewintre, E., Reclusa, P., Calabuig-Fariñas, S., Blasco, A., 
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Reyes, R., Mayo-de-Las-Casas, C., Teixidó, C., Cabrera, C., Marín, E., Vollmer, I., 
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